MiR-133a-5p inhibited cell proliferation in AR-positive prostate cancer cell line VCaP and LNCaP by targeting both FUS and AR, which further decreased the resistance to androgen ablation therapies21. The gene discussed is AR; the disease is Familial prostate cancer.